AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05203575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fast-forwarding in Cycle 2
Description: The fast-forwarding intervention will consist of a projection of future risk of co-morbidities. A visual projection model will be built using archival data available through the Singapore Diabetes Registry. The projection model will use the current profile of the participant to calculate a risk profile for the participant's potential complications and co-morbidities, which will be presented as a pie chart. The tool will also present alternative scenarios to the participant and visualize how the likelihood of complications or co-morbidities would decrease or increases if his/her habits changed. This will provide the motivational aspect of the intervention.~This intervention takes place during Cycle 2 (second 14 weeks).
Study NCT05219695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Harmonic motion imaging guided focused ultrasound (HMIgFUS)
Description: Harmonic motion imaging guided focused ultrasound (HMIgFUS) is a combined treatment and imaging method, in which focused ultrasound (FUS) is used to thermally ablate tissue and harmonic motion imaging (HMI) is used for FUS guidance and monitoring. FUS applies high intensity focused ultrasound waves at its specified target to heat the tissue over a specified duration, causing cell death at the target area. HMI is an elasticity imaging technique which induces dynamic tissue vibrations at the target for tissue elasticity characterization.~One of the inclusion criteria for this study is that participants must be scheduled for surgical excision of their breast tumor. In this study, HMIgFUS will be applied to anesthetized participants immediately prior to their scheduled surgery. HMI imaging will also be performed immediately prior to and after HMIgFUS application.
Study NCT04666298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran sodium
Description: Subcutaneously injected on Day 1, 90 and 270.
Study NCT04666298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously injected on Day 1, 90, and 270.
Study NCT04758338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VUMC telehealth services
Description: Participants will access the CTS link (sent to them via email), which will connect them directly to a videoconference and enable them to see and hear the facilitators and other patients in the group.
Study NCT04758338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: 25-30 participants will be interviewed
Study NCT04758338 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials
Description: Participants will be provided educational materials
Study NCT04593602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Mobilization
Description: Nurse-driven early mobilization activities twice daily
Study NCT04593602 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Mobility Care
Description: Usual mobility care involves following physician orders for mobilization (i.e., bedrest, mobilization to chair with meals, physiotherapy consultation and care) as per local practice.
Study NCT05044988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10342
Description: HS-10342 tablet once daily from Day 1 to 21 of a 28-day cycle
Study NCT05203575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Setting plus Weekly Nudge in Cycle 2
Description: The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 2 (second 14 weeks).
Study NCT05190432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taxifolin
Description: A naturally occurring polyphenol found in apples, onions and other fruits and bark extracts.
Study NCT06375135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TXTXT
Description: Treatment Text (TXTXT) is composed of personalized 2-way SMS text message reminders and encouraging messages. Daily text message reminders will be sent according to the participants medication schedule for six months. A study coordinator will enter the participants phone number in the TXTXT system and set the program to provide daily reminders at the time consistent with the clinical dosing schedule of their ART. Participants will have the option of choosing to create a personalized message that may be changed at any time, because the messages are personalized, they may be in any language the participant desires. Fifteen minutes after this initial message, participants will be asked to send a text message response indicating if they took their medications. Participants responses will be followed by one of a set of randomly selected encouraging messages depending on their affirmative or negative response.
Study NCT06375135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Navigation
Description: Develop an e-Navigation intervention using all three components of CDCs STEPS to Care intervention:(1) patient navigation, (2) care coordination, and (3) HIV-self-management.~Patient Navigation: Remote one-on-one sessions, will help improve medication adherence, access to social services, and prompt re-engagement in care.~Care coordination: Frequent and open communication with the care team. E-navigator will share client progress and needs, support information-sharing and decision-making to improve health outcomes for clients.~HIV self-management: HIV education and guidance with goal setting. E-navigator will help clients build knowledge and skills for self-care, navigating the health care system, and independent health maintenance.~The e-Navigator will meet with participants bi-weekly at first but may meet less frequently over time as barriers are addressed. Meetings will be conducted via videoconferencing and will be used to check in and provide individualized support.
Study NCT05367661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHK336
Description: Tablet
Study NCT05190432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ergothioneine
Description: An amino acid found in mushrooms, oats and some bean varieties.
Study NCT05190432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Microcrystalline cellulose.
Study NCT05900154 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF 120 µg
Description: RSVpreF standard dose level
Study NCT05367661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet
Study NCT04656483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine Video Feedback Intervention
Description: Mother-child dyads will take part into a 6 video-conference sessions of Video Feedback (vVF). The vVF will be standardized according to previously published RCTs. Specifically, the 6 vVFI sessions will be organized in two subsequent phases: 4 sessions based on sharing the focus on different relational themes, and 2 sessions of interactive integration. In more specific terms, during the first set of 4 sessions the psychologist will review with mothers' segments of the videotapes obtained during the baseline assessment and will focus on four different relational themes: responsiveness, physical stimulation, teaching, and parenting experience. During the interactive integration session, the insights developed from the first 4 videoconferences will be applied to the real-time interaction between the parent and his/her infant under the guidance of the psychologist.
Study NCT04656483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Booklet Intervention
Description: Mothers of this condition will receive an informative booklet addressing the same themes included in the experimental intervention (responsiveness, physical stimulation, teaching, and parenting experience), but not tailored on their own infant status.
Study NCT01589627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist Extension Dynasplint
Description: Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
Study NCT05834595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D064, D701
Description: QD, PO
Study NCT05929820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protect Your Colon™
Description: Protect Your Colon™ is an online decision aid focused on CRC screening. The site will first educate patients on the importance of CRC screening and offer information on the advantages and disadvantages of the available test options. Protect Your Colon™ will then present an interactive conjoint analysis-a quantitative survey technique that elucidates how individuals make complex decisions-to precisely determine individuals' latent preferences regarding CRC screening options. Afterwards, the app will generate a personalized report that rank orders the importance of each test attribute (e.g., accuracy, invasiveness, test frequency) in patients' decision making and identifies the screening modality that best matches their preferences. The report will also be shareable with physicians, enabling patients and providers to engage in shared decision making surrounding CRC screening in the clinic.
Study NCT05884632 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Daily Adaptive RadioTherapy
Description: Patients will be treated on the prostate bed with Ethos using daily-adaptive modality with the dose of 59 Gy in 20 daily fractions of 2.95 Gy
Study NCT05954039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Polar Lipid Complex
Description: The study foresees the intake of 2 capsules per day during 84 days
Study NCT05954039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study foresees the intake of 2 capsules per day during 84 days
Study NCT05900154 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF 60 µg
Description: RSVpreF low dose level
Study NCT06380244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anesthesia without opioids
Description: Opioid free general anesthesia
Study NCT06404528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood glucose stress combined with low-dose chemotherapy
Description: By controlling the patient's blood sugar, low-dose chemotherapy is used in a hypoglycemic state. Some necrotic tumor cells produced by chemotherapy can maintain their immunogenicity, further activate innate immunity, produce very strong anticancer effects, and have no cytotoxic reactions to chemotherapy.
Study NCT05303285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 300mg s.c.
Description: Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 300 mg secukinumab s.c. every 4 weeks
Study NCT05303285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab 150mg s.c.
Description: Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 150 mg secukinumab s.c. every 4 weeks
Study NCT05707325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: engineered red blood cell
Description: engineered red blood cell
Study NCT06375135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA) supported e-Navigation.
Description: Participants in the Ecological Momentary Assessment (EMA) supported e- Navigation intervention will be asked to complete 4 to 6-minute EMAs via a secure survey link three times per week to assess adherence barriers in real or near real time. In addition to time-based EMA (study prompted), participants will also be able to submit event based EMAs (participant prompted) at any time. The e-Navigator will review responses to EMAs and remotely assist participants in addressing these barriers within 2 business days.
Study NCT05050474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SARS-CoV-2 Fusion Protein Vaccine
Description: The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
Study NCT06007443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pain related variables assessment
Description: Pressure pain threshold, conditioned pain modulation, temporal summation, and two-point discrimination will be evaluated on the upper trapezius muscle. Average pain intensity will be asked.
Study NCT05713448 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06264622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose
Description: 2 tablets per day during the morning for 12 weeks.
Study NCT06264622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose
Description: 2 tablets per day during the morning for 12 weeks.
Study NCT06264622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets per day during the morning for 12 weeks.
Study NCT04939584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MultiPulse Therapy
Description: Electrical Stimulation
Study NCT06415331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency
Description: Individualized dose of pulsed radiofrequency is given for 6 minutes.
Study NCT06415331 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional therapy for HNP consisting of:~* Acetaminophen~* NSAID: Etoricoxib, celecoxib, meloxicam, diclofenac, ibuprofen~* Muscle relaxant: eperisone, diazepam~* Opioid: codein, tramadol~* Adjuvant analgesics: Amitriptyline, pregabalin, gabapentin~* Physiotherapy: Short wave diathermy, ultrasound diathermy, transcutaneous electrical nerve stimulation, and exercise
Study NCT06415331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: Conventional therapy for HNP consisting of:~* Acetaminophen~* NSAID: Etoricoxib, celecoxib, meloxicam, diclofenac, ibuprofen~* Muscle relaxant: eperisone, diazepam~* Opioid: codein, tramadol~* Adjuvant analgesics: Amitriptyline, pregabalin, gabapentin~* Physiotherapy: Short wave diathermy, ultrasound diathermy, transcutaneous electrical nerve stimulation, and exercise
Study NCT05693220 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zymot Multi sperm separation device
Description: Sperm preparation with Zymot Multi sperm preparation device
Study NCT05693220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Density gradient centrifugation
Description: Sperm preparation with density gradient centrifugation
Study NCT05021224 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Rapidly prototype and test strategies
Description: We will generate strategies for facilitating treatment initiation that address barriers and leverage facilitators, in partnership with a team of experts in behavioral science and implementation science. We will favor simple, established strategies with freely available resources (e.g., Caring Contacts templates) to promote scalability, but will also consider other potential strategies as indicated. We will explore both low- (e.g., manualized text messaging) and high-tech (e.g., electronic health record integrated patient messaging) strategies to maximize relevance across contexts. Next, prototype-strategy designs will be validated through rapid-cycle tests in this real world context and in a manner that is inexpensive and allows us to fail fast and learn quickly. After testing a given implementation strategy, the team will debrief and decide whether to refine or adjust it.
Study NCT05708651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational device [I-IV]
Description: Intra-individual randomised paired crossover evaluation of airway patency with investigational device in volunteer study participants \[I-II\] and study patients \[III-IV\] at low, moderate and deep steady-state sedation \[I-II\] or procedural sedation according to SOC \[III-IV\].
Study NCT05708651 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator [I-IV]
Description: Intra-individual randomised paired crossover evaluation of airway patency with comparator (biteblock \[I-II\] or no device \[II-IV\]) in volunteer study participants \[I-II\] and study patients \[III-IV\] at low, moderate and deep levels of steady-state sedation \[I-II\], and during procedural sedation according to SOC for scheduled colonoscopy \[III\] or ureteral catheterization \[IV\].
Study NCT06504381 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DB107-RRV
Description: Given intracranially (IC) during resection and intravenously (IV) immediately following
Study NCT05773781 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PuraBond
Description: Application of PuraBond to surgical field
Study NCT06321250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX003948
Description: Subjects will receive JMKX003948 tablets until disease progression
Study NCT06504381 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DB107-FC
Description: Given orally (PO)
Study NCT06504381 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Undergo RT
Study NCT06504381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT06504381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo standard of care MRI
Study NCT06504381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Undergo non-investigational tumor resection
Study NCT06651567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1284
Description: ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration
Study NCT06651567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo rapidly disintegrating tablet, taken once daily, sublingual administration
Study NCT06651411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STARS (Scalable Technology for Adolescents and youth to Reduce Stress)
Description: The intervention is a chatbot-based stress management intervention developed by the World Health Organization (WHO). It consists of 10 sessions, which include: Introduction (1), Psychoeducation (2), Emotion Regulation (3, 4), Behavior Activation (5, 6), Managing Problems (7), Thought Challenging (8, 9), and Relapse Prevention (10). Each session consists of psychoeducation and exercise parts. Trained e-helpers contact participants to support them individually weekly.~The effect of the intervention will be compared against a control group that receives basic psychoeducation. The intervention is provided in Lithuanian.
Study NCT06651411 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Basic psychoeducation
Description: Basic psychoeducation includes basic information on stress management.
Study NCT05124782 — intervention group
Intervention type: OTHER
Intervention: Rheumatoid Arthritis Impact of Disease questionnaire
Description: Rheumatoid Arthritis Impact of Disease questionnaire
Study NCT05593432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Study NCT05593432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle cream
Description: Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Study NCT05593432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Study NCT05574153 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Participants will undergo an oxygenation-sensitive cardiac MRI and, during the scan, perform a vasoactive breathing maneuver composed of a period of paced hyperventilation followed by a voluntary maximal breath hold.
Study NCT06247969 — intervention group
Intervention type: DEVICE
Intervention: endotracheal tube
Description: Endotracheal Tube (ETT) is a flexible plastic tube that is inserted through the mouth or nose into the trachea to establish an artificial airway.
Study NCT00934609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: 45 min ergometer cycling at the ventilatory anaerobic threshold 4 times per week for 12 weeks
Study NCT05582603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCT Long COVID
Description: A 15-day training protocol in which every 48 hours participants' complete a series of different cognitive tasks in the form of games selected among a pool of 12 games from CogniFit (CogniFit Inc., San Francisco, USA) whose difficulty level is tailored to each individual by the a patented Individualized Training System™ (ITS) software that automatically chooses the activities and difficulty levels for each person in every session.
Study NCT04814927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copper IUD
Description: Participants randomized to Copper IUD will receive Paragard IUD at Visit 2.